Luke Evnin, Ph.D.
San Francisco Office
Dr. Luke Evnin is co-founder and Managing Director of MPM. He co-founded MPM in 1997 with Dr. Ansbert Gadicke, M.D., and opened the San Francisco office in 1999. Luke’s passion for discovering and advancing groundbreaking drug discovery companies inspires his work and that of the team he and Ansbert have led, which has been the driving force behind building companies such as BioMarin Pharmaceutical, CoStim Pharmaceuticals (acquired by Novartis), Epizyme, Idenix Pharmaceuticals (acquired by Merck), Pacira Pharmaceuticals, Pharmasset (acquired by Gilead), Potenza Therapeutics (acquired by Astellas Pharma) and Radius Health. MPM believes that these companies are among the biggest successes in biotech history – companies that ultimately resulted in helping thousands of patients live longer and with vastly improved lives.
He was the lead investor and has served on the boards of several of MPM’s most successful investments including CoStim, Idun Pharmaceuticals, and Pacira. Over the past five years, as a component of his MPM activities, Luke has been a co-founder of five MPM portfolio companies including Amphivena Therapeutics, Blade Therapeutics, Harpoon Therapeutics, Maverick Therapeutics, and Werewolf Therapeutics. He has contributed as inventor to several of these companies as well as MPM portfolio company Oncorus where he also serves on the Board of Directors.
In recognition of MPM’s novel work to finance and build companies which may have a significant impact on cancer care and cures globally, Luke and Ansbert are recipients of the 2017 Global Oncology Visionary Award. Luke has also devoted significant effort to working with the Scleroderma Research Foundation, serving as its Chairman since 2002. He devotes time to the External Advisory Board at the Lewis-Sigler Institute for Quantitative Genomics External Advisory Board at Princeton and at QB3 at the University of California- San Francisco.
Prior to co-founding MPM, he honed his skills as a venture capitalist at Accel Partners where he focused on emerging healthcare companies. Luke advanced his technical training and launched his interest in curing disease in the Department of Biochemistry at the University of California, San Francisco where he received his Ph.D., and his passion for drug discovery began at Princeton University where he received his A.B. in Molecular Biology.